You are here

Home » Content

Talasemi major tanisi olan hastalarda osteoporoz sikliginin degerlendirilmesi

Determination of osteoporosis frequency among the thalassemia major patients

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2013
DOI: 
10.2399/tahd.13.38247

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective: Thalassemia major is the heaviest form of the tha-lassemias. Anemia, hepatosplenomegaly, spinal deformities and osteoporosis can be seen in the patients with thalassemia major. Our aim is to detect the frequency of osteoporosis among the tha-lassemia major patients. Methods: Patients with diagnosis of thalassemia major were included in the study. Bone mineral density (BMD) scores (T-score and Z-score) less than -2.5 were accepted as osteoporosis and the scores between -1.5 and -2.5 were accepted as osteopenia. Patients were asked if they had any treatment for bone disorders. Results: Total 25 patients with thalasemia major (14 men, 11 women) were included to study. Patients average age was 22.0± 0.90 years. According to BMD scores 16 of our patients had osteoporosis where as 9 patients had osteopenia. None of the patients were screened for osteoporosis and also none of them was taken any supportive bone treatment. Conclusions: Patients with thalasemia major should be screened for osteoporosis which will affect their further life and quality of life and appropriate medications should be given at early stages.
Bookmark/Search this post with
Abstract (Original Language): 
Amac: Talasemilerin en agir tipi talasemi majordur. Talasemi ma-jorlu hastalarda anemi, hepatosplenomegali ve spinal deformiteler gibi kemik deformiteleri yaninda osteoporoz da gorulebilmekte-dir. Amacimiz talasemi major tanisi olan hastalarda osteoporoz sikligini degerlendirmektir. Yontem: Calismaya talasemi major tanisi alip takipte olan bireyler dahil edildi. Kemik mineral dansitesi T ve Z skorunun -2.5'in altinda olmasi osteoporoz, -1 ile -2.5 arasinda olmasi ise osteopeni olarak kabul edildi. Hastalarin osteoporoz agisindan tedavi alip almadiklari sorgulandi. Bulgular: Calismaya 14'u erkek, kadin toplam 25 talasemi major hastasi alindi. Hastalarin yas ortalamasi 22.0±0.90 yildi. Kemik mineral dansitesi skorlarina gore hastalarin 16'sinda hem Z hem de T skorlarina gore osteoporoz, 9 hastada ise osteopeni saptandi. Bu hastalarin higbirisine daha once osteoporoz taramasi yapilmamis ve herhangi bir destek tedavisi de baslanmamisti. Sonuc: Talasemi major hastalarinin kalan hayatlarini ve yasam ka-litesine olan etkileri agisindan kemik dansitometri ile taranmasinin ve uygun tedavilere en erken donemde baslanmasinin onemli ol-dugu gorusundeyiz.
FULL TEXT (PDF): 
PDF icon arastirmax-talasemi-major-tanisi-olan-hastalarda-osteoporoz-sikliginin-degerlendirilmesi.pdf
  • 4
153
156
  • Turkish

REFERENCES

References: 

1. Yapici G, Kurt AO, Oner S, §a§maz T, Bugdayci R, Tamam A. Kronik kan transfuzyonu alan beta-talasemi major ve orak hucreli anemi hastalarinda gorulen komplikasyonlar. Cumhuriyet Tip Dergisi 2009;31:45-51.
2. Aksoy M, Lekin EW, Maurant AE, Lehmann H. Blood groups, hemoglo-bins,and thalassemia in Southern Turkey and Eti Turks. Br Med J 1958;
18;2:937-9.
3. Canatan D. Dunyada ve Turkiye'de talasemi ve anormal hemoglobinler http://www.talasemifederasyonu.org.tr/pdi^tani/1cansinTani.pdf / Eriflim
tarihi: 22.04.2013.
4. Perrotta S, Cappellini MD, Bertoldo F, et al. Osteoporosis in beta-thalas-saemia major patients: analysis of the genetic background. Br J Haematol
2000;111:461-6.
5. Jensen CE, Tuck SM, Agnew JE, et al. High incidence of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 1998;11(Suppl 3):975-7.
6. Carmina E, Di Fede G, Napoli N, et al. Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif Tissue Int. 2004;74:68-71.
7. Vainas I. Bone mineral density of patients with thalassemia major: four-year follow-up. Calcif Tissue Int 1999;64:481-4.
8. Gulati R, Bhatia V, Agarwal SS. Early onset of endocrine abnormalities in beta-thalassemia major in a developing country. J Pediatr Endocrinol Metab
2000;13:651-6.
9. Morabito N, Lasco A, Gaudio A, et al. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. OsteoporosInt 2002;13:644-9.
10. Perifanis V, Vyzantiadis T, Tziomalos K, et al. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with betathalassaemia. Ann Hematol2007;86:23-30.
11. Gaudio A, Morabito N, Xourafa A, et al. Bisphosphonates in the treat¬ment of thalassemia-associated osteoporosis. J Endocrinol Invest 2008;
31:181-4.
12. Trotta A, Corrado A, Cantatore FP. Anabolic therapy of induced osteo¬porosis in beta-thalassaemia major: case report and literature review. [Article in Italian] Reumatismo 2010;62:119-26.
13. Baytan B, Saglam H, Erdol ve ark. Talasemi majorlu vakalarda endok-rin komplikasyonlarin degerlendirilmesi. Giincel Pediatri 2008;6:58-65.
14. Mamtani M, Kulkarni H. Bone recovery after zoledronate therapy in tha-lassemia-induced osteoporosis: a meta-analysis and systematic review.
Osteoporos Int 2010;21:183-7.
Turkiye Aile Hekimligi Dergisi | Turkish Journal of Family Practice | Cilt 17 | Sayi 4 | 2013
155
15. Terpos E, Voskaridou E. Treatment options for thalassemia patients with
osteoporosis. Ann N Y Acad Sci 2010;1202:237-43.
16. Hatun S, Islam O, £izmecioglu F, et al. Subclinical vitamin D deficiency is increased in adolescent girls who wear concealing clothing. J Nutr
2005;135:218-22.
17. Kurt M, Comertoglu I, Sarp U, Yalgin P, Dinger G. Osteoporozlu hastalarda D vitamini duzeyleri. Tiirk Osteoporoz Dergisi 2011;17:68-70.
18. Haidar R, Musallam KM, Taher AT. Bone disease and skeletal complica¬tions in patients with, thalassemia major. Bone 2011;48:425-32.
19. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta thalassemia major. Osteoporos Int 2001;12:570-5.
20. Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993;341:
801-5.
21. Soliman AT, El Banna N, Abdel Fattah M, El Zalabani MM, Ansari BM.
Bone mineral density in prepubertal children with beta-thalassemia: cor¬relation with growth and hormonal data. Metabolism 1998;47:541-8.
22. Toumba M, Skordis N. Osteoporosis syndrome in thalassaemia major: an
overview. J Osteoporos2010;2010:537673.
23. Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev
2008;6(Suppl 1):158-69.

Thank you for copying data from http://www.arastirmax.com